Botanix Pharmaceuticals Management
Management criteria checks 2/4
Botanix Pharmaceuticals' CEO is Howie McKibbon, appointed in Aug 2023, has a tenure of 1.33 years. total yearly compensation is A$3.92M, comprised of 15.3% salary and 84.7% bonuses, including company stock and options. directly owns 0.22% of the company’s shares, worth $949.95K. The average tenure of the management team and the board of directors is 1 years and 5.4 years respectively.
Key information
Howie McKibbon
Chief executive officer
AU$3.9m
Total compensation
| CEO salary percentage | 15.3% |
| CEO tenure | 1.3yrs |
| CEO ownership | 0.2% |
| Management average tenure | 1yrs |
| Board average tenure | 5.4yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | AU$4m | AU$602k | -AU$14m |
| Mar 31 2024 | n/a | n/a | -AU$12m |
| Dec 31 2023 | n/a | n/a | -AU$10m |
| Sep 30 2023 | n/a | n/a | -AU$10m |
| Jun 30 2023 | AU$1m | AU$542k | -AU$9m |
| Mar 31 2023 | n/a | n/a | -AU$10m |
| Dec 31 2022 | n/a | n/a | -AU$11m |
| Sep 30 2022 | n/a | n/a | -AU$12m |
| Jun 30 2022 | AU$585k | AU$126k | -AU$13m |
Compensation vs Market: Howie's total compensation ($USD2.45M) is about average for companies of similar size in the US market ($USD2.16M).
Compensation vs Earnings: Howie's compensation has increased whilst the company is unprofitable.
CEO
Howie McKibbon
1.3yrs
Tenure
AU$3,923,813
Compensation
Dr. Howie McKibbon serves as Chief Executive Officer since August 24, 2023 and was its Chief Operating Officer since October 2022 until August 24, 2023. He served as Chief Commercial Officer at Botanix Pha...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| MD & Executive Chairman | 5.4yrs | AU$612.70k | 0.59% $ 2.6m | |
| Chief Executive Officer | 1.3yrs | AU$3.92m | 0.22% $ 950.0k | |
| Chief Financial Officer | less than a year | AU$186.22k | no data | |
| Executive Director | 4.8yrs | AU$357.12k | 4.1% $ 17.7m | |
| Senior Vice President of Pharmaceutical Development | 3.9yrs | no data | no data | |
| Chief Medical Adviser | 2.9yrs | no data | no data | |
| Chief Business Officer | less than a year | no data | no data | |
| Head of Corporate Affairs | less than a year | no data | no data | |
| Head of HCP Marketing & Sales Training | less than a year | no data | no data | |
| Company Secretary | 1.7yrs | no data | no data | |
| Director of Sales Operations | less than a year | no data | no data |
1.0yrs
Average Tenure
58yo
Average Age
Experienced Management: BXPH.F's management team is not considered experienced ( 1 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| MD & Executive Chairman | 5.4yrs | AU$612.70k | 0.59% $ 2.6m | |
| Executive Director | 4.8yrs | AU$357.12k | 4.1% $ 17.7m | |
| Independent Non-Executive Director | 5.8yrs | AU$61.57k | 0.12% $ 515.4k | |
| Non Executive Director | 8.4yrs | AU$227.16k | 1.04% $ 4.5m | |
| Non-Executive Director | 2.8yrs | AU$88.49k | 0.12% $ 506.2k |
5.4yrs
Average Tenure
54yo
Average Age
Experienced Board: BXPH.F's board of directors are considered experienced (5.4 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 01:41 |
| End of Day Share Price | 2024/12/23 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Botanix Pharmaceuticals Limited is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| John Hester | Bell Potter |